Gadobutrol
MCL
University Hospital, BonnSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the MCL cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DOTATOC Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 | CCC |
Baff-R Car-T Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | CC |
cd22 car-transduced t cells Essen Biotech | Phase 1/2 | CC |
Promethazine Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | CC |
Anti-Cd19/Cd22 Car-T Cells Essen Biotech | Phase 1/2 | CC |
Epcoritamab Genmab | Phase 1/2 | CC |
Hmpl-760 Hutchmed | Phase 1 | CC |
ANTI-CD47/CD19 BISPECIFIC MONOCLONAL ANTIBODY TG-1801 TG Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
Gadobutrol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →